Radionuclide therapy for neuroendocrine tumors
M Cives, J Strosberg - Current oncology reports, 2017 - Springer
Peptide receptor radionuclide therapy (PRRT) is a form of systemic radiotherapy that allows
targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin …
targeted delivery of radionuclides to tumor cells expressing high levels of somatostatin …
Radiolabeled somatostatin analogue therapy of gastroenteropancreatic cancer
L Bodei, DJ Kwekkeboom, M Kidd, IM Modlin… - Seminars in nuclear …, 2016 - Elsevier
Peptide receptor radionuclide therapy (PRRT) has been utilized for more than two decades
and has been accepted as an effective therapeutic modality in the treatment of inoperable or …
and has been accepted as an effective therapeutic modality in the treatment of inoperable or …
Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu …
S Ballal, MP Yadav, C Bal, RK Sahoo… - European journal of …, 2020 - Springer
Purpose The objective of this study was to investigate and present the early results on the
efficacy, safety, and quality of life of 225 Ac-DOTATATE targeted alpha therapy (TAT) in …
efficacy, safety, and quality of life of 225 Ac-DOTATATE targeted alpha therapy (TAT) in …
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
C Cullinane, K Waldeck, L Kirby, BE Rogers, P Eu… - Scientific reports, 2020 - nature.com
Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients
with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though …
with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though …
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE
M Sansovini, S Severi, A Ianniello, S Nicolini… - European journal of …, 2017 - Springer
Abstract Purpose Lu-DOTATATE (Lu-PRRT) is a valid therapeutic option in differentiated
pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic …
pancreatic neuroendocrine tumors (P-NETs). FDG PET seems to be an important prognostic …
Dosimetric quantities in neuroendocrine tumors over treatment cycles with 177Lu-DOTATATE
D Roth, J Gustafsson, CF Warfvinge… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Tumor dosimetry was performed for 177Lu-DOTATATE with the aims of better understanding
the range and variation of the tumor-absorbed doses (ADs), how different dosimetric …
the range and variation of the tumor-absorbed doses (ADs), how different dosimetric …
Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
DMV Huizing, BJ de Wit-van der Veen, M Verheij… - EJNMMI research, 2018 - Springer
Background The main challenge for systemic radiation therapy using radiopharmaceuticals
(SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue …
(SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue …
Neuroendocrine breast carcinoma: a rare but challenging entity
E Trevisi, A La Salvia, L Daniele, MP Brizzi… - Medical Oncology, 2020 - Springer
Breast carcinoma with neuroendocrine differentiation, also known as neuroendocrine breast
carcinoma (NEBC), includes a heterogeneous group of rare tumors, which account for 2–5 …
carcinoma (NEBC), includes a heterogeneous group of rare tumors, which account for 2–5 …
Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review
B Camus, AS Cottereau, LJ Palmieri… - Journal of clinical …, 2021 - mdpi.com
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that
allows the administration of targeted radionuclides into tumor cells that express a large …
allows the administration of targeted radionuclides into tumor cells that express a large …
Targeted systemic treatment of neuroendocrine tumors: current options and future perspectives
AD Herrera-Martínez, J Hofland, LJ Hofland… - Drugs, 2019 - Springer
Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the
bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical …
bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical …